
Zanidatamab Plus Chemotherapy Shows Promising Anti-Tumor Activity in Treatment of HER2-Mutated Breast Cancer
Zanidatamab (Ziihera; Jazz Pharmaceuticals, Inc) plus chemotherapy demonstrated a manageable safety profile with promising antitumor activity and durable responses in heavily pretreated patients with human epidermal growth factor receptor 2 (HER2)-mutated …